Vitrolife Group Annual and Sustainability Report 2022

Vitrolife Group has today published its Annual and Sustainability Report for 2022.

The Annual and Sustainability Report is now available digitally in English and Swedish at www.vitrolife.com. The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish.

Vitrolife Group has chosen not to print or distribute a hard copy of the Annual Report. Those who are unable to access the Annual Report digitally can request a print-out of the Annual Report by contacting Vitrolife Group at investors@vitrolife.com or call +46 (0) 31 721 80 00.

Gothenburg, Sweden
March 30, 2023
VITROLIFE AB (publ)

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 30-03-2023 08:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group’s products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.